P53 Accumulation and Proliferating-cell Nuclear Antigen Expression in Human Lung Cancer

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 1995 Jan 1

PMID 7797603

Citations 4

Authors

T Wiethege

B Voss

K M Muller

Affiliations

Soon will be listed here.

Abstract

Mutations in the p53 gene are currently the commonest genetic alterations in human malignant tumors, including non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Alterations of the protein induced by gene mutations enables the mutant protein to become more stable, resulting in the accumulation of P53 in quantities detectable by immunohistochemistry. Although previous studies document the accumulation of P53 in lung cancer, there is little information regarding the usual frequency of accumulation based on a comprehensive number of lung tumors. A total of 328 paraffin-embedded lung carcinoma specimens were analyzed for P53 accumulation and for the expression of the proliferating-cell nuclear antigen (PCNA) by standard immunohistochemistry. Among 49 SCLC, 35% were positive for p53 and 51% were positive for PCNA. Out of 279 NSCLC, 43% showed a positive P53 immunoreaction and 72% displayed detectable amounts of PCNA. In squamous-cell carcinomas a statistically significant increased accumulation of P53 was found compared to adenocarcinomas (P = 0.001). Among the 233 PCNA-positive tumors the relative number of P53-positive specimens was higher compared to the total number of tumors. Since immunohistochemical investigations should contribute to the improvement of the clinical diagnosis and treatment or give information on the prognosis, we conclude from our results that it seems to be legitimate to assess the P53 status exclusively in the specimens positive for PCNA. Immunohistochemical investigations under consideration of the PCNA status yielded good and fast recognition of p53 mutations leading to intracellular P53 protein accumulation.

Citing Articles

From Proteomic Analysis to Potential Therapeutic Targets: Functional Profile of Two Lung Cancer Cell Lines, A549 and SW900, Widely Studied in Pre-Clinical Research.

Korrodi-Gregorio L, Soto-Cerrato V, Vitorino R, Fardilha M, Perez-Tomas R PLoS One. 2016; 11(11):e0165973.

PMID: 27814385 PMC: 5096714. DOI: 10.1371/journal.pone.0165973.

Fisetin modulates mitochondrial enzymes and apoptotic signals in benzo(a)pyrene-induced lung cancer.

Ravichandran N, Suresh G, Ramesh B, Manikandan R, Choi Y, Vijaiyan Siva G Mol Cell Biochem. 2014; 390(1-2):225-34.

PMID: 24496750 DOI: 10.1007/s11010-014-1973-y.

Modulation of lung molecular biomarkers by beta-carotene in the Physicians' Health Study.

Liu C, Wang X, Mucci L, Gaziano J, Zhang S Cancer. 2009; 115(5):1049-58.

PMID: 19142877 PMC: 2649969. DOI: 10.1002/cncr.24061.

P53 expression in stage I squamous cell lung cancer.

Moldvay J, Strausz J, Egervary M, Agocs L, Bocsi J, Schaff Z Pathol Oncol Res. 1998; 4(1):8-13.

PMID: 9555114 DOI: 10.1007/BF02904688.

References

Iggo R, Gatter K, Bartek J, Lane D, Harris A . Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet. 1990; 335(8691):675-9. DOI: 10.1016/0140-6736(90)90801-b. View

BENNETT W, Hollstein M, He A, Zhu S, Resau J, Trump B . Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer. Oncogene. 1991; 6(10):1779-84. View

Kupryjanczyk J, Thor A, Beauchamp R, Merritt V, Edgerton S, Bell D . p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci U S A. 1993; 90(11):4961-5. PMC: 46633. DOI: 10.1073/pnas.90.11.4961. View

Lane D, CRAWFORD L . T antigen is bound to a host protein in SV40-transformed cells. Nature. 1979; 278(5701):261-3. DOI: 10.1038/278261a0. View

Viallet J, Minna J . Dominant oncogenes and tumor suppressor genes in the pathogenesis of lung cancer. Am J Respir Cell Mol Biol. 1990; 2(3):225-32. DOI: 10.1165/ajrcmb/2.3.225. View

DeLeo A, Jay G, Appella E, DuBois G, Law L, Old L . Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A. 1979; 76(5):2420-4. PMC: 383613. DOI: 10.1073/pnas.76.5.2420. View

Vahakangas K, Samet J, Metcalf R, Welsh J, BENNETT W, Lane D . Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet. 1992; 339(8793):576-80. DOI: 10.1016/0140-6736(92)90866-2. View

Levine A, Perry M, Chang A, Silver A, Dittmer D, Wu M . The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer. 1994; 69(3):409-16. PMC: 1968876. DOI: 10.1038/bjc.1994.76. View

Takahashi T, DAmico D, Chiba I, Buchhagen D, Minna J . Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer. J Clin Invest. 1990; 86(1):363-9. PMC: 296731. DOI: 10.1172/JCI114710. View

10.

Takahashi T, Suzuki H, Hida T, Sekido Y, Ariyoshi Y, Ueda R . The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene. 1991; 6(10):1775-8. View

11.

Harbour J, Lai S, Whang-Peng J, Gazdar A, Minna J, Kaye F . Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science. 1988; 241(4863):353-7. PMC: 5480895. DOI: 10.1126/science.2838909. View

12.

Mitsudomi T, Oyama T, Kusano T, Osaki T, Nakanishi R, Shirakusa T . Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst. 1993; 85(24):2018-23. DOI: 10.1093/jnci/85.24.2018. View

13.

Vojtesek B, Bartek J, Midgley C, Lane D . An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods. 1992; 151(1-2):237-44. DOI: 10.1016/0022-1759(92)90122-a. View

14.

Chiba I, Takahashi T, Nau M, DAmico D, Curiel D, Mitsudomi T . Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene. 1990; 5(10):1603-10. View

15.

BENNETT W, Colby T, Travis W, Borkowski A, Jones R, Lane D . p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res. 1993; 53(20):4817-22. View

16.

Midgley C, Fisher C, Bartek J, Vojtesek B, Lane D, Barnes D . Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J Cell Sci. 1992; 101 ( Pt 1):183-9. DOI: 10.1242/jcs.101.1.183. View

17.

Quinlan D, Davidson A, Summers C, WARDEN H, Doshi H . Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 1992; 52(17):4828-31. View

18.

Hall P, McKee P, Menage H, Dover R, Lane D . High levels of p53 protein in UV-irradiated normal human skin. Oncogene. 1993; 8(1):203-7. View

19.

Volm M, Mattern J, Hecker S, Pommerenke E . Association of p53 expression with proliferative activity and poor-prognosis in patients with squamous-cell lung carcinomas. Int J Oncol. 2011; 5(3):533-8. View

20.

Waseem N, Lane D . Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci. 1990; 96 ( Pt 1):121-9. DOI: 10.1242/jcs.96.1.121. View